Publications by authors named "A De Pover"

Claim this Profile
C
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
Christine Fritsch, Alan Huang, Christian Chatenay-Rivauday, Christian Schnell, Anupama Reddy, Alain De Pover

Mol Cancer Ther· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
Andrea Vaupel, Guido Bold, Alain De Pover, Thérèse Stachyra-Valat, Joanna Hergovich Lisztwan

Bioorg Med Chem Lett· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.
Rita Andraos, Zhiyan Qian, Débora Bonenfant, Joëlle Rubert, Eric Vangrevelinghe, Alain De Pover

Cancer Discov· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction.
Pascal Furet, Patrick Chène, Alain De Pover, Thérèse Stachyra Valat, Joanna Hergovich Lisztwan

Bioorg Med Chem Lett· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
Oliver Weigert, Andrew A Lane, Liat Bird, Nadja Kopp, Bjoern Chapuy, Alain De Pover

J Exp Med· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis